



**University of Dundee**

## **Indications for Systemic Fluoroquinolone Therapy in Europe and Prevalence of Primary-Care Prescribing in France, Germany and the UK**

Morales, Daniel R; Slattery, Jim; Pinheiro, Luis; Kurz, Xavier; Hedenmalm, Karin

*Published in:*  
Clinical Drug Investigation

*DOI:*  
[10.1007/s40261-018-0684-7](https://doi.org/10.1007/s40261-018-0684-7)

*Publication date:*  
2018

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*

Morales, D. R., Slattery, J., Pinheiro, L., Kurz, X., & Hedenmalm, K. (2018). Indications for Systemic Fluoroquinolone Therapy in Europe and Prevalence of Primary-Care Prescribing in France, Germany and the UK: Descriptive Population-Based Study. *Clinical Drug Investigation*, 38(10), 927-933.  
<https://doi.org/10.1007/s40261-018-0684-7>

### **General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

# Indications for systemic fluoroquinolone therapy in Europe and prevalence of primary care prescribing in France, Germany and the UK: descriptive population based study

**Daniel Morales**, <sup>1</sup>Pharmacovigilance and Epidemiology Department, European Medicines Agency, London, UK; <sup>2</sup>Population Health Sciences Division, University of Dundee, UK

**Jim Slattery**, Pharmacovigilance and Epidemiology Department, European Medicines Agency, London, UK

**Luis Pinheiro**, Pharmacovigilance and Epidemiology Department, European Medicines Agency, London, UK

**Xavier Kurz**, Pharmacovigilance and Epidemiology Department, European Medicines Agency, London, UK

**Karin Hedenmalm**, Business Data and Analytics Department, European Medicines Agency, London, UK

## **CORRESPONDING AUTHOR**

**Dr Daniel Morales**, Pharmacovigilance and Epidemiology Department, European Medicines Agency, 30 Churchill Pl, Canary Wharf, London E14 5EU, UK

**TEL:** +442036606000

**EMAIL:** { [HYPERLINK "mailto:Daniel.Morales@ext.ema.europa.eu"](mailto:Daniel.Morales@ext.ema.europa.eu) }

**RUNNING TITLE:** Fluoroquinolone indications in Europe

## **MAIN POINTS**

- Milder infections such as acute sinusitis, acute bronchitis and uncomplicated UTI are common indications for systemic fluoroquinolone therapy in Europe.
- Although fluoroquinolone prescribing has fallen in France, Germany and UK, trends appear to vary by country and by indication.

## **ABSTRACT**

### **Background and Objectives**

In the United States the benefit-risk profile of fluoroquinolones for treating patients with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infections (uUTI) is considered unfavorable. However, the number of fluoroquinolone products in the EU indicated and prescribed for these infections is uncertain. The objective was to provide data on indications for fluoroquinolones in Europe and examine the prevalence of prescribing in France, Germany and the UK.

### **Method**

Descriptive analysis of indications for systemic fluoroquinolone antibiotic across the European Economic Area (EEA) and descriptive analysis of systemic fluoroquinolone antibiotic prescribing in France, Germany and UK electronic health records (2000-2015).

### **Results**

All EEA countries had fluoroquinolone products indicated for acute sinusitis, acute bronchitis or uUTI, with differences in the number of products between countries for: acute sinusitis (19.5%-51.9%); acute bronchitis (22.2%-73.4%); and uUTI (52.0%-89.1%). The prevalence of fluoroquinolone prescribing for the treatment of respiratory tract infections (RTI) appeared to fall with time in all countries and for UTI in France and UK only. Changes were greatest in the UK. In France, Germany and the UK respectively: acute sinusitis accounted for 29.5%, 20.6% and 40.7% of all oral fluoroquinolone prescriptions for upper RTIs; acute bronchitis accounted for 63.0%, 83.0% and 89.9% of all fluoroquinolone prescriptions for lower RTIs; uUTI accounted for 83.3%, 89.9%, 32.2% of all fluoroquinolone prescriptions for UTIs.

### **Conclusion**

Large numbers of fluoroquinolone products in Europe are listed for the treatment of milder infections such as acute bronchitis, acute sinusitis and uUTI. Among the countries assessed, fluoroquinolones were commonly prescribed for these conditions and potentially should lead to a review of therapeutic guidelines.

## **1. INTRODUCTION**

Fluoroquinolone antibiotics inhibit type II topoisomerases required for bacterial DNA replication, transcription and repair.[1] They are widely prescribed treatments for a broad range of infections including those affecting the urinary, respiratory and gastrointestinal systems. Due to their broad spectrum of activity they are effective against a wide range of infections. However, as with most medicines fluoroquinolones have the potential to cause adverse reactions, which may be persistent in some patients. Adverse reactions from systemic fluoroquinolone exposure may involve tendons, muscles, joints and nerves, and may include reactions such as tendon rupture, peripheral neuropathy and neuropsychiatric reactions.[2-8] Furthermore, there have been increasing concerns over antimicrobial resistance resulting from antibiotic prescribing with resistance rates displaying wide variations in Europe depending on the bacterial species, antimicrobial group and geographical region.[9] The benefit-risk profile for the use of systemic fluoroquinolone antibiotics may differ for less severe infections such as those with and without complicated infections, for example cystitis and pyelonephritis.

These concerns have resulted in the European Medicines Agency reviewing the persistence of side effects known to occur with fluoroquinolone antibiotics.[10] Data are therefore required on patterns of fluoroquinolone use, particular for these less severe indications. A United States (U.S.) Food and Drug Administration (FDA) safety review using evidence from prescribing data, published literature and the FDA's Adverse Events Reporting System previously concluded that fluoroquinolone antibiotics may be associated with potentially long-term serious side effects when administered via systemic routes of administration (i.e. tablets, capsules, and intravenous formulations).[11] In May 2016, the FDA advised that because of the potential for long-term serious adverse reactions, the benefit-risk profile of fluoroquinolones for treating patients with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infections (uUTI) was unfavorable.[12] It was decided by the FDA that fluoroquinolones should not be prescribed for these indications unless no other alternatives are available

and that the product labels and medication guides for all fluoroquinolone antibacterial drugs be updated in the U.S. to reflect new safety information. Off-label use of systemic fluoroquinolone antibiotics may also occur, the extent of which may vary between country. The aim of this study was to provide data on potential indications for systemic fluoroquinolone products authorized in Europe with an emphasis on acute sinusitis, acute bronchitis and uUTI and to examine the prevalence of fluoroquinolone prescribing for these conditions in France, Germany and the UK.

## **2. METHODS**

### **Data sources**

#### *Article 57 database*

The European Medicines Agency (EMA) Article 57 database contains information on all medicinal products for human use in Europe, which marketing authorisation holders are required to submit and is based upon the content of their Summary of Product Characteristics (SPCs).[13] The Article 57 database is considered around 97% complete as determined through comparison with national databases in a study conducted by the European Medicines Agency. Products are recorded per country and contain descriptions of indications for use for that product in that country.

#### *Databases*

A full description of each database is contained within supplementary file. In brief the IMS<sup>®</sup> Disease Analyzer France and Germany (versions June 2016) databases contain anonymised electronic primary care electronic medical record data on diagnoses (coded using the International Classification of Disease (ICD) coding system) and prescriptions from a representative panel of general practitioners (GPs) from each country commencing from 1997 and 1992 respectively. Data are representative in terms of age, gender and geographical distribution. The UK THIN database (version May 2016) contains electronic primary care medical records extracted from general practices covering approximately 6% of the UK population. Data are representative of the UK population in terms of age,

deprivation, and geographical distribution. Diagnoses, symptoms, and other relevant health information are recorded using the Read Code clinical classification system, a hierarchical classification system.

### **Populations**

Patients were included from the IMS<sup>®</sup> Disease Analyzer France and Germany cohort if they had a consultation date between the start and end of the study period (01.01.2000 and 31.12.2015 respectively) with cohort start determined by the date of the first recording; all patients with a consultation during the year were used as population denominator. For the UK database, cohort entry was defined as the latest of the following dates: start of the study period (01.01.2000); or date of registration with a general practice. Cohort exit was defined by the earliest of the following dates: deregistration from the general practice; death; date of last electronic data collection; end of the study period (31.12.2015).

### **Exposures**

In the IMS<sup>®</sup> Disease Analyzer France and Germany databases, prescriptions for incident fluoroquinolones were identified by EphMRA ATC code J01G1 (non-topical fluoroquinolone administration) and by gemsript codes in the UK. Only incident fluoroquinolone prescription episodes were evaluated, defined as a prescription for a systemic fluoroquinolone with no prescription in the previous 30 days. In the UK, incident fluoroquinolones were predominantly prescribed second line whilst in France and Germany there was a higher proportion of first line use. Please refer to the supplementary material for further methodological details.

### **Fluoroquinolone indications**

Indications were identified from the Article 57 database by searching disease descriptions for each fluoroquinolone product. Clinical indications were identified in the electronic medical record databases by identifying ICD10 and Read codes recorded in people prescribed a systemic fluoroquinolone antibiotic. Disease descriptions and codes were first

broadly categorised into the following pre-specified groups based upon a scoping exercise: upper respiratory tract infections (URTI); lower respiratory tract infections (LRTI); urinary tract infections (UTI); ear infections; gastrointestinal infections (including hepatobiliary infections); genital infections (excluding testicular and prostatic infections considered separately); testicular infections; prostatic infections; skin and soft tissue infections; bone infections; and other indications. Codes that could not be readily grouped into one of the above categories were considered as unclassified. Codes were screened by two reviewers, with a third reviewer used to reach consensus if needed. For upper respiratory tract infections (URTI), lower respiratory tract infections (LRTI) and urinary tract infections (UTI), indications were then categorised into acute sinusitis, acute bronchitis and uUTIs as described in the supplementary material.

## **Analysis**

A descriptive analysis of indications for treatment with systemic fluoroquinolone products in the Article 57 database was undertaken for each country in the EEA. The prevalence of incident systemic fluoroquinolone prescribing in France, Germany and the UK was calculated for each indication category as a percentage of the total number of incident fluoroquinolone prescriptions identified with a systemic route of administration. The descriptive analysis of indications recorded in the Article 57 database was then compared to clinical indications through routine electronic prescribing for France, Germany and the UK with yearly trends in the prevalence of fluoroquinolone prescribing plotted. In a post-hoc analysis, Joinpoint regression using the grid search method and permutation testing for model selection was used to determine at what point statistically significant changes in trend occurred in each country for uUTI, acute bronchitis and acute sinusitis.<sup>(13)</sup> All analyses contained within this study are based on "own calculation" (i.e. analysis was conducted by the study authors and not by the database providers). The study was registered in the EU register of post-authorization studies (number EUPAS20889).

### **3. RESULTS**

#### *Listed indications for treatment with fluoroquinolones in Europe*

The Article 57 database contained a total of 2694 fluoroquinolone product entries across 30 EEA countries of which 2353 had a systemic routes of administration (1762 (74.9%) oral; 591 (25.1%) intravenous). The most frequently recorded fluoroquinolone active substances were ciprofloxacin (45.3%), levofloxacin (26.4%), moxifloxacin (12.4%), ofloxacin (9.0%) and norfloxacin (3.6%) (supplementary table 2).

These 2694 product entries contained a sum total of 36830 indication descriptions (mean 13.7 per product). All EEA countries had one or more fluoroquinolone product with indicated for the treatment of acute sinusitis, acute bronchitis and uUTI that varied according to the type of active substance, with norfloxacin licenced for uUTI only (supplementary table 3). This ranged from: 19.5% to 51.9% for acute sinusitis; 22.2% to 73.4% for acute bronchitis; and 52.0% to 89.1% for uUTI (table 1).

#### *Prevalence of fluoroquinolone prescribing in France, Germany and the UK*

The most frequently prescribed fluoroquinolone in France was norfloxacin (26.9%) with ciprofloxacin more commonly prescribed in Germany (51.0%) and in the UK (89.4%) (supplementary table 4). Clinical indications were identified in 70.1%, 83.5% and 62.1% of incident fluoroquinolone prescriptions from the French, German and UK databases respectively. The most frequent indication for fluoroquinolone treatment in France, Germany and the UK was for UTI (58.7%, 43.4% and 33.5% respectively). Figure 1 shows the proportion of incident fluoroquinolone prescriptions for the treatment of LRTI, URTI and UTI along with the subset of milder infections of acute bronchitis, acute sinusitis and uncomplicated UTI in France, Germany and the UK. Fluoroquinolones were prescribed for the treatment of acute bronchitis, acute sinusitis and uUTI in: 10.0%, 4.7% and 48.9% of instances respectively in France; in 29.9%, 3.4% and 39.0% of instances respectively in Germany; and in 3.7%, 1.7% and 19.9% of instances respectively in the UK. Figure 2



shows the proportion of incident fluoroquinolone prescriptions for the treatment of the remaining indication categories in France, Germany and the UK. The proportion of incident fluoroquinolone prescriptions for different indications varied by substance within each country, with levofloxacin and moxifloxacin mainly being used for the treatment of URTI and LRTI, whilst norfloxacin and ofloxacin was mainly use for the treatment of UTI (supplementary tables 5-7, supplementary figure 1).

#### *Trends in systemic fluoroquinolone prescribing in France, Germany and the UK*

Trends in systemic fluoroquinolone prescribing are shown in figure 2. There were rising trends in fluoroquinolone prescribing until 2007 in France and UK, and 2009 in Germany. Fluoroquinolone prescribing then fell in France and the UK for, particularly for the treatment of LRTI, URTI and UTIs whilst in Germany changes were smaller and for UTI remained relatively stable. In absolute terms the numbers of fluoroquinolone prescriptions for indications other than for RTI and UTI were small. Similar trends in fluoroquinolone prescribing for the treatment of acute bronchitis, acute sinusitis and uUTI are shown in figure 3. Of the three indications, uUTI was the most common indication for fluoroquinolone prescribing in all three countries. In France there were significant changes in trend in 2006 and 2014 for uUTI, and in 2004 and 2009 for acute bronchitis and acute sinusitis. In Germany, there were significant changes in trend in 2005 and 2010 for uUTI, 2005 for acute bronchitis and in 2005 and 2013 for acute sinusitis. In the UK, there were significant changes in trend in 2007 and 2011 for uUTI, and in 2007 and 2012 for acute bronchitis and acute sinusitis (supplementary table 8).

Comparisons between listed indications and those in clinical practice demonstrated that apart from ciprofloxacin, all other fluoroquinolone active substance were prescribed to treat infections in a greater number of indication categories than listed suggesting off-label use although in absolute terms some of this usage was small.

#### **4. DISCUSSION**

In light of recent decisions in the U.S. on the use of fluoroquinolone antibiotics for the treatment of acute sinusitis, acute bronchitis and uUTI, we performed a descriptive analysis of listed indications for treatment with systemic fluoroquinolone products across the EEA and examined the prevalence of fluoroquinolone prescribing in France, Germany and the UK. This study found that fluoroquinolone products across the EEA are frequently indicated for the treatment of acute sinusitis, acute bronchitis and uUTI, the extent of which appeared to vary by country and by fluoroquinolone active substance. Fluoroquinolones were also prescribed for these milder infections in France, Germany and the UK with some evidence of off-label use to treat infections in other systems. Although the prevalence of fluoroquinolone prescribing has fallen over recent years, variation in changes occurred by country and by indication, with trends in fluoroquinolone prescribing for the treatment of UTIs in Germany remaining fairly stable.

Although a large percentage of fluoroquinolone products across the EEA had a listed indication related to the recent FDA safety communication, it is perhaps not the number of products but how fluoroquinolones are prescribed in clinical practice which is more important. This study shows that compared with France and Germany, fluoroquinolone prescribing has fallen more steeply in the UK since 2008, which may be related to antibiotic stewardship interventions and changes in antibiotic guidelines in response to tackling *Clostridium difficile* infection.[15, 16] This has important implications in reducing antibiotic resistance which may result in treatment failure and delays in clinical recovery after treatment with antibiotics, however high quality trials for clinician-targeted interventions to influence antibiotic prescribing behaviour for respiratory tract infections in primary care may still be required to provide robust evidence of their comparative effectiveness.[17, 18]

Overall, the most common indication for fluoroquinolones was for the treatment of UTI. However, at substance level levofloxacin and moxifloxacin were more commonly used to

treat LRTIs with norfloxacin being the most commonly prescribed fluoroquinolone in France compared to ciprofloxacin in the UK and Germany. This is also important because the benefit-risk for fluoroquinolone antibiotics will not only depend upon the severity of infections but also on the comparable safety of different fluoroquinolone active substances. Fluoroquinolones were prescribed for the treatment of URTI in France and Germany more often than in the UK where prescribing for the treatment of GI infections was more common. In relative terms, acute bronchitis appeared to account for 66.9% and 53.6% of all fluoroquinolones prescribed for the treatment of LRTIs in Germany and France compared to only 7.6% in the UK. Similarly, uUTI appeared to account for 89.9% and 83.3% of all fluoroquinolone prescribing for the treatment of UTIs in Germany and France compared to 59.5% in the UK.

Variation in prescribing is important and there are several potential factors that may influence the use of fluoroquinolone antibiotics including clinical guidelines, local drug formularies, and differences in prescribing culture. For example, a study of recommendations for empiric first-choice antibiotic treatment of uUTIs in six European countries found considerable differences in recommendation and most countries offered more than one first-choice antibiotic, with nitrofurantoin being listed as an option in five countries and fluoroquinolones in one country only.[19] In our study, fluoroquinolones were more often prescribed as first-line therapy in France and Germany than in the UK. Antimicrobial resistance rates display wide variations in Europe depending on the bacterial species, antimicrobial group and geographical region.[9] In general, lower resistance rates have been reported by northern European countries compared to southern European countries that are considered likely related to variations in antimicrobial use, infection prevention and control practices, and dissimilarities in diagnostic and healthcare utilisation patterns in the countries. Antimicrobial resistance can result from antimicrobial use but may also drive the choice of different antibiotics that may explain some of the differences observed in our study. However, we analysed data from France, Germany and the UK only because we had access to these databases. Although differences in the first-choice

antibiotic may depend upon different factors such as the local patterns of bacterial resistance, they are perhaps less likely to be a factor in deciding between different fluoroquinolones. In a qualitative study exploring reasons to prescribe fluoroquinolone antibiotics, interviews were conducted among GPs from high and average fluoroquinolone prescribing practices in the UK.[20] This study found that prescribing fluoroquinolone antibiotics, as opposed to narrow-spectrum antibiotics, depended upon several clinical considerations, perceptions of patient expectations and organizational influences including prioritising patient needs and considering long term consequences. Understanding variation in the choice of fluoroquinolone antibiotic prescribed is also important because they may have different properties and it cannot be assumed that all fluoroquinolones are equally effective or equally safe.

Fluoroquinolones may cause serious adverse reactions including peripheral neuropathy, tendinopathies and psychiatric reactions.[2-7] Factors to consider when assessing their benefit risk may include overall effectiveness, the frequency and severity of infections treated with fluoroquinolones and the frequency and severity of adverse effects. Bacterial infections such as acute sinusitis, acute bronchitis and uUTI are common and can be relatively mild. There is also the potential for misdiagnosis of viral causes for sinusitis and bronchitis. Part of assessing benefit risk may also depend upon whether these drugs are used first- or second-line. In this regard, it was recently noted in an editorial that antibiotic stewardship programmes may help to reduce inappropriate use of fluoroquinolone prescribing and indeed variation, and by improving the level of knowledge of antibiotics among community prescribers is required particularly with increasing antibiotic resistance in health care settings.[21].

This study has several limitations. First, the definitions of acute bronchitis, acute sinusitis and uUTI used in this study were based on definitions which included unspecified, conditions (bronchitis and UTI) which potential could introduce some misclassification. However, codes for sinusitis and UTI are commonly recorded in primary care records and

it is likely many will be for acute and uncomplicated infections respectively based upon our primary care experience. Second, identifying clinical indications in the electronic medical records relied upon screening of codes using a look-back period because clinical indications were not routinely linked to the prescription. However, we carefully tailored our look-back periods based upon the frequency of codes and coding practices observed within each database. Despite this, we cannot confirm the indication with either the patient or the health care professional that would ideally be required to undergo proper validation. Lastly, we used only broad high-level indication categories rather than disease-specific indications as these were considered too extensive to analyse and report, particularly when our focus specifically related to sinusitis, bronchitis and uUTI. In this regard, significant variation in prescribing is likely to exist within indication categories, the extent of which is uncertain.

## **CONCLUSION**

In conclusion, many fluoroquinolones products with a systemic route of administration across the EEA appear to have an indication for the treatment of milder infections including acute sinusitis, acute bronchitis or uUTI. In clinical practice, fluoroquinolones are not infrequently prescribed for these indications which may have implications for clinical guidelines, and antibiotic stewardship interventions.

## **COMPLIANCE WITH ETHICAL STANDARDS**

### **Source of funding**

No source of funding

### **Conflicts of interest**

Daniel Morales has no conflicts of interest.

Jim Slattery has no conflicts of interest.

Luis Pinheiro has no conflicts of interest.

Xavier Kurz has no conflicts of interest.

Karin Hedenmalm has no conflicts of interest.

### **Ethical approval**

Approval to conduct the studies using anonymised data was granted by the Scientific Review Committees of The Health Improvement Network (THIN) and IMS® (17THIN032).

### **Disclaimer**

The views expressed in this article are the personal views of the author(s) and may not be not be understood or quoted as reflecting the views of the EMA or one of its committees or working parties.

## 5. REFERENCES

1. Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. *Clin Infect Dis*. 2001;32 Suppl 1:S9-S15.
2. Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. *BMJ Open*. 2015;5(11):e010077.
3. Sode J, Obel N, Hallas J, Lassen A. Use of fluoroquinolone and risk of Achilles tendon rupture: a population-based cohort study. *Eur J Clin Pharmacol*. 2007;63:499-503.
4. Arabyat RM, Raisch DW, McKoy JM, Bennett CL. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system. *Expert Opin Drug Saf*. 2015;14(11):1653-60.
5. Ali AK. Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis. *Ann Epidemiol*. 2014 Apr;24(4):279-85.
6. Hedenmalm K, Spigset O. Peripheral sensory disturbances related to treatment with fluoroquinolones. *J Antimicrob Chemother*. 1996;37(4):831-7.
7. Etminan M, Brophy JM, Samii A. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. *Neurology*. 2014;83(14):1261-3.
8. Joint Formulary Committee. British National Formulary Section 5.1.12 Quinolones (online) London: BMJ Group and Pharmaceutical Press  
<<http://www.medicinescomplete.com>> [Accessed on 17/01/2017].
9. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2016 Report. 2017. Available at:  
<https://ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2016> . [Accessed 20/07/2018].
10. European Medicines Agency. Quinolone and fluoroquinolone article 31 referral. 2017. Available at: { HYPERLINK  
"<http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Quinolone>

s\_and\_fluoroquinolones\_containing\_medicinal\_products/human\_referral\_prac\_000065.jsp&mi  
d=WC0b01ac05805c516f" [}](#). [Accessed 01/09/2017]

11. FDA Joint Meeting of the Antimicrobial Drugs Advisory Committee (formerly known as the Anti-Infective Drugs Advisory Committee) and Drug Safety and Risk Management Advisory Committee Meeting Announcement. November 2015. <{ HYPERLINK "http://www.fda.gov/AdvisoryCommittees/Calendar/ucm465275.htm" [}](#)> [Accessed 17/01/2017].
12. FDA drug safety communication (online). July 2016. <{ HYPERLINK "http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm" [}](#)> [Accessed 17/01/2017].
13. European Medicines Agency. Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the European Medicines Agency in accordance with Article 57(2) of Regulation (EC) No. 726/2004. <{ HYPERLINK "http://www.ema.europa.eu/docs/en\_GB/document\_library/Other/2012/03/WC500123681.pdf" [}](#)> [Accessed 17/01/2017].
14. Joinpoint Trend Analysis Software. <https://surveillance.cancer.gov/joinpoint/> [Accessed on 30 May 2017].
15. Public Health England. Clostridium difficile: guidance, data and analysis. Available at: <https://www.gov.uk/government/collections/clostridium-difficile-guidance-data-and-analysis>. [Accessed 01/08/2017].
16. Hernandez-Santiago V, Marwick CA, Patton A, Davey PG, Donnan PT, Guthrie B. Time series analysis of the impact of an intervention in Tayside, Scotland to reduce primary care broad-spectrum antimicrobial use. *J Antimicrob Chemother.* 2015;70:2397-404.
17. van Hecke O, Wang K, Lee JJ, Roberts NW, Butler CC. Implications of Antibiotic Resistance for Patients' Recovery From Common Infections in the Community: A Systematic Review and Meta-analysis. *Clin Infect Dis.* 2017;65:371-382.
18. Tonkin-Crine SK, Tan PS, van Hecke O, Wang K, Roberts NW, McCullough A, Hansen MP, Butler CC, Del Mar CB. Clinician-targeted interventions to influence antibiotic



prescribing behaviour for acute respiratory infections in primary care: an overview of systematic reviews. *Cochrane Database Syst Rev.* 2017;9:CD012252.

19. McQuiston Haslund J, Rosborg Dinesen M, Sternhagen Nielsen AB, Llor C, Bjerrum L. Different recommendations for empiric first-choice antibiotic treatment of uncomplicated urinary tract infections in Europe. *Scand J Prim Health Care.* 2013;31:235-40.
20. Wood F, Simpson S, Butler CC. Socially responsible antibiotic choices in primary care: a qualitative study of GPs' decisions to prescribe broad-spectrum and fluoroquinolone antibiotics. *Fam Pract.* 2007;24:427-34.
21. Tillotson GS. FDA and the safe and appropriate antibiotic use of fluoroquinolones. *Lancet Infect Dis.* 2016;16(3):e11-2.

**Table 1. Percentage of systemic fluoroquinolone products with an indication for acute sinusitis, acute bronchitis or uncomplicated UTI in each EEA country.**

Country	Number of products	Acute Sinusitis (%)	Acute Bronchitis (%)	Uncomplicated UTI (%)
Austria	102	29.4	59.8	68.6
Belgium	167	36.5	41.3	71.3
Bulgaria	76	39.5	54.0	69.8
Croatia	42	26.2	59.5	59.5
Cyprus	62	35.5	48.4	80.7
Czech Republic	41	19.5	39.0	58.5
Denmark	50	24.0	50.0	52.0
Estonia	35	37.1	68.6	71.4
Finland	51	25.5	54.9	60.8
France	141	27.0	49.7	73.1
Germany	236	32.6	53.0	69.9
Greece	135	20.0	28.2	79.3
Hungary	79	51.9	65.8	70.9
Iceland	18	34.6	65.5	89.1
Ireland	55	37.7	67.9	81.6
Italy	271	29.7	54.1	67.6
Latvia	37	30.8	56.4	69.2
Lithuania	39	39.3	44.6	62.5
Luxembourg	56	21.4	53.6	75.0
Malta	56	38.7	65.3	79.8
Netherlands	124	33.3	22.2	61.1
Norway	18	30.4	46.4	62.3
Poland	69	39.4	73.4	80.3
Portugal	203	28.0	55.9	72.0
Romania	93	22.9	50.0	73.0
Slovakia	48	42.2	57.8	62.2
Slovenia	45	37.9	61.5	62.1
Spain	182	26.2	65.6	68.9
Sweden	61	35.4	63.4	75.6
UK	82	29.4	59.8	68.6

Data from the Article 57 database

## FIGURE LEGENDS

**Figure 1. Proportion of total fluoroquinolone prescribing for the treatment of A) LRTI, B) URTI, and C) UTI and for the milder infections of acute bronchitis, acute sinusitis and uncomplicated UTI in France, Germany and the UK.**

LRTI=Lower respiratory tract infection. URTI=upper respiratory tract infection. UTI=urinary tract infection. uUTI=uncomplicated UTI.

**Figure 2. Proportion of total fluoroquinolone prescribing for the treatment of the remaining indication groups in France, Germany and the UK.**

GI=gastrointestinal.

**Figure 3. Trends in systemic fluoroquinolone prescribing by indication in France, Germany and the UK.**

LRTI/URTI=lower/upper respiratory tract infection. GI=gastrointestinal infection. UTI=urinary tract infection. Analyses based upon own calculation.

**Figure 4. Trends in fluoroquinolone prescribing for acute bronchitis, acute sinusitis and uncomplicated UTI in France, Germany and the UK.**

Medium grey diamond = Uncomplicated UTI. Dark grey square = Acute bronchitis. Light grey triangle = Acute sinusitis. Analyses based upon own calculation.